RealFeedApp MNA-001 study shows age-linked markers shifting toward younger levels
A Phase 1 trial of Muna Therapeutics' drug MNA-001 showed that age-linked markers in elderly volunteers' cerebrospinal fluid shifted toward levels seen in younger, healthy people. The oral small-molecule drug targeting TREM2 demonstrated safety and reached the brain.
- Field
- ageing and longevity
- What they did
- Researchers gave elderly volunteers a pill called MNA-001 that targets the protein TREM2 and found that some brain-related markers shifted toward levels seen in younger people.
- Why it matters
- This could be useful for understanding how to slow down brain aging, as impairments in TREM2 function are linked to an increased risk of Alzheimer's disease.
#muna therapeutics#mna-001#tremp2#microglia#aging#phase 1 trial
